| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Revenue | 357.8 | 327.3 |
| Gross profit | 220.9 | 194.7 |
| Profit before tax | 62.9 | 51.3 |
| Net income | 46.3 | 38.7 |
| EPS (diluted, $ a share) | $1.00 | $0.81 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | +19.7% |
|---|---|
| Revenue, year on year | +9.3% |
| Gross margin | 61.7% |
| Operating margin | 21.0% |
10-Q filed with the SEC, NYSE: HAE. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Haemonetics Corp: key numbers
- Share price
- $121.34Close, Nov 16
- Market cap
- $5.53B
- Shares outstanding
- 45.54MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Haemonetics Corp
All →Haemonetics VP, CAO Farris Maryanne Maunsell Sells $101K of Stock
Farris Maryanne Maunsell, VP, CAO, sold 836 shares of Haemonetics Corp at $120.99 a share, worth $101K in total on Nov 11, 2026. Shares held after the trade: 5,828 (-12.5%).
- Value
- $101K
- Shares
- 836
- Price
- $120.99
- Role
- VP, CAO
- Holding change
- -12.5%
- Trade date
- Nov 11, 2026
Haemonetics Earnings Call: Key Takeaways
Haemonetics delivered strong Q2 results with 10% organic revenue growth, raising full-year guidance driven by a major CSL relationship expansion and Persona Plus adoption despite near-term margin pressure from growth investments.
- Call
- Nov 5, 2026, 8:00 AM ET
Haemonetics Financial Results
Haemonetics reported second quarter fiscal 2027 revenue of $358 million, a 9% increase driven by strong performance in its Apheresis business. The company achieved GAAP diluted EPS of $1.00 and adjusted diluted EPS of $1.35, benefiting from gross margin expansion and the transformation of its product portfolio toward higher-margin offerings.
- Term
- Q2 2027
“Our second-quarter and first-half results reflect significant momentum across our businesses. Expansion of our CSL relationship and recent innovation milestones in both Apheresis and MedSurg strengthen our competitive position and create powerful new opportunities. With multiple catalysts for growth, we are focused on executing for our customers and translating our momentum into sustained success and shareholder value.”
Chris Simon, Haemonetics’ CEO
Haemonetics Business Update
Haemonetics provided a status update on its non-exclusive supply agreement with CSL Plasma, noting that CSL expects to complete the rollout of NexSys PCS devices and Persona PLUS disposables across all its U.S. collection centers by the end of 2027. The company maintained its existing fiscal 2027 guidance and plans to provide a detailed financial impact update during its November 2026 earnings call.
- Counterparty
- CSL Plasma Inc.
- Term
- through end of calendar year 2027